Publications by authors named "Adriana O Mitchell"
Introduction: Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within non-Hispanic White (NHW) populations. Here we provide an extensive survey of the proteomic landscape of AD across diverse racial/ethnic groups.
Methods: Two cortical regions, from multiple centers, were harmonized by uniform neuropathological diagnosis.
Introduction: Multi-omics studies in Alzheimer's disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked Black Americans (BA) and Latin Americans (LA), who are disproportionately affected by AD.
Methods: To bridge this gap, Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD) expanded brain multi-omics profiling to multi-ethnic donors.
Article Synopsis
- Alzheimer's disease (AD) primarily affects diverse populations, but most research has focused on the non-Hispanic White demographic, necessitating a broader understanding across different racial and ethnic groups.
- This study involved analyzing brain tissues from donors of various racial backgrounds, utilizing mass spectrometry to examine protein levels in key brain regions related to AD, resulting in a large dataset of proteins associated with the disease.
- The findings highlighted significant protein elevations linked to AD across all groups, emphasizing the importance of ethnoracial-specific differences in protein expression for future research and potential treatments.
Introduction: Multi-omics studies in Alzheimer's disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked African Americans (AA) and Latin Americans (LA), who are disproportionately affected by AD.
Methods: To bridge this gap, Accelerating Medicines Partnership in AD (AMP-AD) expanded brain multi-omics profiling to multi-ethnic donors.
Progressive supranuclear palsy (PSP) is a neurodegenerative parkinsonian disorder characterized by cell-type-specific tau lesions in neurons and glia. Prior work uncovered transcriptome changes in human PSP brains, although their cell-specificity is unknown. Further, systematic data integration and experimental validation platforms to prioritize brain transcriptional perturbations as therapeutic targets in PSP are currently lacking.
View Article and Find Full Text PDF